Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CStone Pharmaceuticals (HK:2616)
HKEX:2616
Holding HK:2616?
Track your performance easily
2616 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$0.80 - HK$2.95
Previous CloseHK$2
Volume1.64M
Average Volume (3M)2.40M
Market Cap
HK$2.52B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Mar 20, 2025EPS Estimate
-HK$0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares OutstandingN/A
10 Day Avg. Volume1,654,300
30 Day Avg. Volume2,401,774
Standard Deviation0.17
R-Squared0.12
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)8.23
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CStone Pharmaceuticals News
PremiumCompany Announcements
CStone Partners with Pharmalink to Expand Global Reach
PremiumCompany Announcements
CStone Pharmaceuticals Showcases Breakthrough in Cancer Therapy
PremiumCompany Announcements
CStone Pharmaceuticals to Unveil Promising Lymphoma Drug Data
PremiumCompany Announcements
CStone Gains UK Approval for Key Lung Cancer Drug
PremiumCompany Announcements
CStone Pharmaceuticals’ Breakthrough with Sugemalimab StudyPremiumCompany Announcements
CStone CEO Boosts Confidence with Significant Share Purchase
PremiumCompany Announcements
CStone Pharmaceuticals Unveils Patent for Innovative Cancer Therapy
PremiumCompany Announcements
CStone Pharmaceuticals Awards Employee Stock OptionsOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.12% Mutual Funds
― Other Institutional Investors
98.69% Public Companies and
Individual Investors
2616 FAQ
What was CStone Pharmaceuticals’s price range in the past 12 months?
CStone Pharmaceuticals lowest stock price was HK$0.80 and its highest was HK$2.95 in the past 12 months.
What is CStone Pharmaceuticals’s market cap?
Currently, no data Available
When is CStone Pharmaceuticals’s upcoming earnings report date?
CStone Pharmaceuticals’s upcoming earnings report date is Mar 20, 2025 which is in 113 days.
How were CStone Pharmaceuticals’s earnings last quarter?
CStone Pharmaceuticals released its earnings results on Aug 23, 2024. The company reported HK$0.011 earnings per share for the quarter, beating the consensus estimate of -HK$0.107 by HK$0.118.
Is CStone Pharmaceuticals overvalued?
According to Wall Street analysts CStone Pharmaceuticals’s price is currently Overvalued.
Does CStone Pharmaceuticals pay dividends?
CStone Pharmaceuticals does not currently pay dividends.
What is CStone Pharmaceuticals’s EPS estimate?
CStone Pharmaceuticals’s EPS estimate is -HK$0.03.
How many shares outstanding does CStone Pharmaceuticals have?
CStone Pharmaceuticals has 1,284,237,200 shares outstanding.
What happened to CStone Pharmaceuticals’s price movement after its last earnings report?
CStone Pharmaceuticals reported an EPS of HK$0.011 in its last earnings report, beating expectations of -HK$0.107. Following the earnings report the stock price went down -2.29%.
Which hedge fund is a major shareholder of CStone Pharmaceuticals?
Currently, no hedge funds are holding shares in HK:2616
---
CStone Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.35%
12-Months-Change
Fundamentals
Return on Equity
-26.64%
Trailing 12-Months
Asset Growth
-8.06%
Trailing 12-Months
Company Description
CStone Pharmaceuticals
CStone Pharmaceuticals is engaged in the development and commercialization of innovative tumor immunotherapy and molecular-targeted drugs. It has been operating in one reportable segment, the research and development of complex biopharmaceutical products.
---
2616 Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Akeso, Inc.
―
Ascletis Pharma, Inc.
―
Dragon Rise Group Holdings Ltd.
―
---